Immunogenomic classification of colorectal cancer and therapeutic implications

Jessica Roelands, Peter J.K. Kuppen, Louis Vermeulen, Cristina Maccalli, Julie Decock, Ena Wang, Francesco M. Marincola, Davide Bedognetti*, Wouter Hendrickx

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

103 Citations (Scopus)

Abstract

The immune system has a substantial effect on colorectal cancer (CRC) progression. Additionally, the response to immunotherapeutics and conventional treatment options (e.g., chemotherapy, radiotherapy and targeted therapies) is influenced by the immune system. The molecular characterization of colorectal cancer (CRC) has led to the identification of favorable and unfavorable immunological attributes linked to clinical outcome. With the definition of consensus molecular subtypes (CMSs) based on transcriptomic profiles, multiple characteristics have been proposed to be responsible for the development of the tumor immune microenvironment and corresponding mechanisms of immune escape. In this review, a detailed description of proposed immune phenotypes as well as their interaction with different therapeutic modalities will be provided. Finally, possible strategies to shift the CRC immune phenotype towards a reactive, antitumor orientation are proposed per CMS.

Original languageEnglish
Article number2229
JournalInternational Journal of Molecular Sciences
Volume18
Issue number10
DOIs
Publication statusPublished - 24 Oct 2017

Keywords

  • Colorectal cancer
  • Combination therapy
  • Consensus molecular subtypes
  • Immune contexture
  • Immunologic constant of rejection
  • Immunotherapy
  • Tumor microenvironment

Fingerprint

Dive into the research topics of 'Immunogenomic classification of colorectal cancer and therapeutic implications'. Together they form a unique fingerprint.

Cite this